Cargando…
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK...
Autores principales: | Alkharabsheh, Omar, Alsayed, Alhareth, Morlote, Diana M., Mehta, Amitkumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985758/ https://www.ncbi.nlm.nih.gov/pubmed/33567487 http://dx.doi.org/10.3390/curroncol28010081 |
Ejemplares similares
-
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021) -
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023) -
Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
por: Dias, Ajoy Lawrence, et al.
Publicado: (2013) -
Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review
por: Din, Mohammad Ammad Ud, et al.
Publicado: (2022) -
Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)